loader from loading.io

Episode 326: Intramuscular Injections: The Oncology Nurse’s Role

The ONS Podcast

Release Date: 08/23/2024

Episode 344: ONS 50th Anniversary: Founding Leaders’ Vision and Challenges, Then and Now show art Episode 344: ONS 50th Anniversary: Founding Leaders’ Vision and Challenges, Then and Now

The ONS Podcast

“Who would think that we would be here 50 years later? And with the excitement that I think will build even more, I’m so humbled and honored to talk to young nurses. And their excitement—the same excitement that we had in the very beginning—is inherent. I hope that our legacy will be that we are able to pass on this tremendous gift of our careers to new nurses,” Cindi Cantril, MPH, RN, OCN®-Emeritus, founding ONS member and first vice president, told Darcy Burbage, DNP, RN, AOCN®, CBCN®, chair of the ONS 50th Anniversary Committee, during a conversation about the history of...

info_outline Episode 343: Cancer Cachexia Considerations for Nurses and Patients show art Episode 343: Cancer Cachexia Considerations for Nurses and Patients

The ONS Podcast

“There’s actually quite a bit of debate about what the clinical definition of cancer cachexia is, but in its simplest definition of cachexia in this case is cancer-induced body weight loss. You can have cachexia in other diseases, for heart failure or renal failure, but it's basically tumor-induced metabolic derangement that leads to inflammation and often anorexia, which produces body weight loss,” Teresa Zimmers, PhD, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about cancer cachexia. Music Credit: “” by Kevin...

info_outline Episode 342: What It’s Like to Serve on the Leadership Development Committee show art Episode 342: What It’s Like to Serve on the Leadership Development Committee

The ONS Podcast

“The Leadership Development Committee (LDC) is one of the most important member volunteer positions in the organization, and here’s why: The main purpose of the LDC is to recruit, vet, and select ONS Board of Directors. As some of you may know, it has been three years since we moved away from members voting for directors,” ONS member Nancy Houlihan, MA, RN, AOCN®, 2020–2022 ONS president and former director of nursing practice at Memorial Sloan Kettering Cancer Center in New York, NY, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a...

info_outline Episode 341: Pharmacology 101: HER Inhibitors show art Episode 341: Pharmacology 101: HER Inhibitors

The ONS Podcast

“Key thing here is that it was discovered that when you have gene amplification of HER2 you get a resultant overexpression of that HER protein and that overexpression leads to a driver for certain cancers. So, when you have an overexpression of HER2, it leads to the cancer being more aggressive,” ONS member Rowena “Moe” Schwartz, PharmD, BCOP, FHOP, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about HER inhibitors.  Music Credit: “” by Kevin MacLeod  Licensed under Creative Commons by Attribution...

info_outline Episode 340: What It’s Like to Plan an ONS Conference show art Episode 340: What It’s Like to Plan an ONS Conference

The ONS Podcast

“Don’t be afraid of applying, even if you’ve never planned a conference before, and you think, ‘Well, I have no idea what I’m doing.’ You probably know more than you think you do. You probably have more connections than you think you do, and it is such a worthwhile experience,” Colleen Erb, MSN, CRNP, ACNP-BC, AOCNP®, hematology and oncology nurse practitioner at Jefferson Health Asplundh Cancer Pavilion in Willow Grove, PA, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, conferences oncology clinical specialist at ONS, during a conversation about serving on a planning committee...

info_outline Episode 339: A Lesson on Labs: How to Monitor and Educate Patients With Cancer show art Episode 339: A Lesson on Labs: How to Monitor and Educate Patients With Cancer

The ONS Podcast

“The nurse’s role in monitoring the lab values really depends on the clinics you're working at, but really when our patients are receiving treatment, especially in the infusion center, the nurses should be looking at those lab values prior to treatment being started,” Clara Beaver, DNP, RN, AOCNS®, ACNS-BC, clinical nurse specialist at Karmanos Cancer Center in Michigan told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS during a conversation about how to monitor and educate patients with cancer.  Music Credit: “” by Kevin MacLeod  ...

info_outline Episode 338: High-Volume Subcutaneous Injections: The Oncology Nurse’s Role show art Episode 338: High-Volume Subcutaneous Injections: The Oncology Nurse’s Role

The ONS Podcast

“Although the patient is spending a little less time in the clinic, the administration actually requires the nurse to be at the chairside the entire time. This has allowed nurses to spend potentially uninterrupted time to sit and converse with the patients that they may not have had with an IV infusion. It’s been a wonderful unintentional outcome from the development of the large-volume subcutaneous injections,” Crystal Derosier, MSN, RN, OCN®, clinical specialist at Dana-Farber Cancer Institute, in Boston, MA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing...

info_outline Episode 337: Meet the ONS Board of Directors: Haynes, Wilson, and Yackzan show art Episode 337: Meet the ONS Board of Directors: Haynes, Wilson, and Yackzan

The ONS Podcast

“The gravity of the responsibility was realized when you walked into the boardroom and you’re there to make decisions, and the perspective you have to take shifts. Of course, I bring to the table my expertise and my perspective, but the decision-making and strategy behind it is really geared at sustaining the organization and moving us towards our mission, which is to advance excellence in oncology nursing and quality cancer care. Being able to reframe your perspective a little bit around those decisions is something that you don’t realize until you’re there to do that,” ONS...

info_outline Episode 336: Pharmacology 101: EGFR Inhibitors show art Episode 336: Pharmacology 101: EGFR Inhibitors

The ONS Podcast

“Under normal conditions, EGFR [epidermal growth factor receptor] is in an auto-inhibited state. And it’s only when it’s needed that it’s upregulated. But when you have cancers that there is either a mutation in the EGFR or an overexpression, what you see is a dysregulation of normal cellular processes. So you get overexpression or switching on of prosurvival or antiapoptotic responses,” Rowena “Moe” Schwartz, professor of pharmacy practice at James L. Winkle College of Pharmacy at the University of Cincinnati in Ohio, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology...

info_outline Episode 335: Ultrasound-Guided IV Placement in the Oncology Setting show art Episode 335: Ultrasound-Guided IV Placement in the Oncology Setting

The ONS Podcast

Episode 335: Ultrasound-Guided IV Placement in the Oncology Setting “Much like many experienced oncology nurses, I learned how to do IVs with palpation. I got really good at it. And so I thought, there’s no way I need this ultrasound. But we know now that our patients are sicker. There are more DIVA patients, or difficult IV access patients. We’ve got to put the patient first, and we’ve got to use the best technology. So I’ve really come full circle with my thinking. In fact, now it’s like driving a car without a seatbelt,” MiKaela Olsen, DNP, APRN-CNS, AOCNS®, FAAN,...

info_outline
 
More Episodes

“One of the big misconceptions is that this is just a quick shot. And this is a patient’s treatment regimen. So, it is not just a quick shot. It is treatment, and we need to get it where it is supposed to go so that the patient’s, cancer treatment is not impacted,” Caroline Clark, MSN, APRN, OCN®, AG-CNS, EBP-C, director of evidence-based practice and inquiry at ONS, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about administering intramuscular (IM) injections in oncology.

Music Credit: “Fireflies and Stardust” by Kevin MacLeod

Licensed under Creative Commons by Attribution 3.0 

Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by August 23, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Learning outcome: Learners will report an increase in knowledge related to the administration of antineoplastic medications by IM injection.

Episode Notes

To discuss the information in this episode with other oncology nurses, visit the ONS Communities. 

To find resources for creating an Oncology Nursing Podcast Club in your chapter or nursing community, visit the ONS Podcast Library.

To provide feedback or otherwise reach ONS about the podcast, email [email protected].

Highlights From This Episode

“More frequently oncology nurses are using intramuscular injection techniques when giving certain hormonal therapies for cancer treatment and for cancer symptom management. Some examples of those are fulvestrant for treatment of hormone receptor–positive, HER2-negative breast cancer, leuprolide as androgen deprivation therapy in prostate cancer. This is also used off label for breast cancer management. It’s used for premenopausal ovarian suppression and also in noncancerous conditions like endometriosis and uterine fibroids.” TS 2:04

“Inadvertent injection into the sciatic nerve is one of the most common causes of sciatic injury. It has significant morbidity associated with it. And even for drugs like fulvestrant, the prescribing information notes reports of sciatica, neuropathic pain, neuralgia, peripheral neuropathy—all related to dorsogluteal injection.” TS 6:09

“When administering an IM injection to someone who is cachectic, you don’t want the subcutaneous tissue to bunch up. So you can kind of stretch this over with your nondominant hand, as in the Z-track method, and then grasp the muscle between your thumb and index finger. That’s going to help you ensure that you’re getting that muscular injection.” TS 11:47

 “Z-track is a way that you inject so that there’s no leakage back out into the subcutaneous space. Clean your area as usual. You displace the skin and the subcutaneous tissue that’s over that muscle, and then you inject slowly into the muscle. Once you remove the needle, then you release that tissue. And it kind of seals it over and prevents that leakage back up into the subcutaneous space.” TS 14:19

“I think ventrogluteal injection is less commonly done. There are documented issues with confidence in landmarking and giving it to that site, so practice is necessary. A great way to identify the ventrogluteal site on yourself to start is to stand up and put your hand at your side. You feel for the top of that iliac crest. Place your hand right below the iliac crest and then just start marching in place. You’re going to feel that muscle contraction right away. This also works when you abduct your leg. Abducting the leg is helpful when a patient is at a side-lying position to give a ventrogluteal injection—you feel that muscle contraction.” TS 17:06

“I wish it would be front of mind to encourage adverse event reporting related to any injection you’re giving. These types of reports—they drive improvement measures and monitoring. And then when things are underreported, it leads us to anecdotal reports. So really monitoring any change, trying to get some baseline data on adverse events with injection is really important.” TS 26:32